Iowa Senate passes harsh gifts, data ban bill

Share this article:
Iowa Senate passes harsh gifts, data ban bill
Iowa Senate passes harsh gifts, data ban bill
Iowa's state Senate passed a healthcare bill containing some of the toughest restrictions on drug company contacts with physicians yet.

Senate File 389, which passed by a vote of 30-18, must still pass through the state's House of Representatives and be signed into law by the governor.

The bill would establish an “insurance exchange” and expand public health insurance for children. It would also establish an “evidence-based drug education program,” require that companies report all payments to physicians for continuing education and clinical research and ban on all other gifts and compensation, along with the provision of prescribing data for commercial purposes.

Manufacturers, wholesalers and agents acting on their behalf would be prohibited from offering any gift to healthcare practitioners under the bill, with exception to: payments to sponsors of “significant educational, scientific or policy-making conference or seminar,” provided the payment is not made directly to a practitioner; “Reasonable honoraria and payment of the reasonable expenses” of faculty at such conferences or seminars “pursuant to an explicit contract with specific deliverables which are restricted to scientific issues, not marketing efforts”; and compensation for “bona fide clinical trials.”

The bill requires manufacturers to disclose to the state's department of administrative services an annual report on all gifts or payments covered under the exemptions to the prohibition.

The disclosure of individual identifying information for the marketing of prescribed products would be banned, and violators could be fined up to $50,000.

The Iowa law is, in some respects, even harsher than the Massachusetts bill passed earlier this month, which includes prohibitions on most gifts and meals for healthcare practitioners from drug and device companies, tough reporting requirements and an “opt out” provision allowing prescribers to withhold their prescribing data from commercial use.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...